15 research outputs found

    Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties

    Get PDF
    A series of functionalized phenyl oxazole derivatives was designed, synthesized and screened in vitro for their activities against LSD1 and for effects on viability of cervical and breast cancer cells, and in vivo for effects using zebrafish embryos. These compounds are likely to act via multiple epigenetic mechanisms specific to cancer cells including LSD1 inhibition

    The ketone body Ī²-hydroxybutyrate does not inhibit synuclein mediated inflammasome activation in microglia

    No full text
    Parkinson's disease (PD) is recognized as the most common neurodegenerative movement disorder and results in debilitating motor deficits. The accumulation and spread of neurotoxic synuclein aggregates in the form of Lewy bodies is a key pathological feature of PD. Chronic activation of the NLRP3 inflammasome by protein aggregates is emerging as a major pathogenic mechanism in progressive neurodegenerative disorders and is considered an important therapeutic target. Recently the ketone body, beta-hydroxy butyrate (BHB), was shown to efficiently inhibit the NLRP3 inflammasome in macrophages, and in vivo models of inflammatory disease. Furthermore, BHB can readily cross the blood brain barrier suggesting that it could have therapeutic benefits for the management of PD. In this study, we evaluated if BHB could inhibit chronic microglial inflammasome activation induced by pathological fibrillar synuclein aggregates. Interestingly, we found that BHB treatment almost completely blocked all aspects of inflammasome activation and pyroptosis induced by ATP and monosodium urate (MSU) crystals, consistent with previously published reports in macrophages. Surprisingly however, BHB did not inhibit inflammasome activation and release of IL-1 beta or caspase-1 induced by synuclein fibrils. Our results demonstrate that BHB does not block the upstream pathways regulating inflammasome activation by synuclein fibrils and suggest that synuclein mediated inflammasome activation proceeds via distinct mechanisms compared to traditional NLRP3 activators such as ATP and MSU

    Construction of phenoxazine rings containing nitro and sulfonic acid groups leading to phenoxazine-3-sulfonamide derivatives: Their evaluation as novel and potential insulin secretagogues

    No full text
    A series of N-(alkyl/aryl/heteroaryl)-1-nitro-10H-phenoxazine-3- sulfonamides was designed, synthesized and evaluated for its hypoglycemic, hyperglycemic and oral anti-diabetic activities. These compounds were prepared via the construction of a phenoxazine ring containing nitro and sulfonic acid groups in a single step followed by further transformations. One of these compounds exhibited promising anti-diabetic activities comparable to glibenclamide and increased serum insulin levels indicating its potential as a novel insulin secretagogue. This journal i

    The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins

    No full text
    Microglial NLRP3 inflammasome activation is emerging as a key contributor to neuroinflammation during neurodegeneration. Pathogenic protein aggregates such as Ī²ā€amyloid and Ī±ā€synuclein trigger microglial NLRP3 activation, leading to caspaseā€1 activation and ILā€1Ī² secretion. Both caspaseā€1 and ILā€1Ī² contribute to disease progression in the mouse SOD1G93A model of amyotrophic lateral sclerosis (ALS), suggesting a role for microglial NLRP3. Prior studies, however, suggested SOD1G93A mice microglia do not express NLRP3, and SOD1G93A protein generated ILā€1Ī² in microglia independent to NLRP3. Here, we demonstrate using Nlrp3ā€GFP gene knockā€in mice that microglia express NLRP3 in SOD1G93A mice. We show that both aggregated and soluble SOD1G93A activates inflammasome in primary mouse microglia leading caspaseā€1 and ILā€1Ī² cleavage, ASC speck formation, and the secretion of ILā€1Ī² in a doseā€ and timeā€dependent manner. Importantly, SOD1G93A was unable to induce ILā€1Ī² secretion from microglia deficient for Nlrp3, or pretreated with the specific NLRP3 inhibitor MCC950, confirming NLRP3 as the key inflammasome complex mediating SOD1ā€induced microglial ILā€1Ī² secretion. Microglial NLRP3 upregulation was also observed in the TDPā€43Q331K ALS mouse model, and TDPā€43 wildā€type and mutant proteins could also activate microglial inflammasomes in a NLRP3ā€dependent manner. Mechanistically, we identified the generation of reactive oxygen species and ATP as key events required for SOD1G93Aā€mediated NLRP3 activation. Taken together, our data demonstrate that ALS microglia express NLRP3, and that pathological ALS proteins activate the microglial NLRP3 inflammasome. NLRP3 inhibition may therefore be a potential therapeutic approach to arrest microglial neuroinflammation and ALS disease progression

    The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins

    No full text
    Microglial NLRP3 inflammasome activation is emerging as a key contributor to neuroinflammation during neurodegeneration. Pathogenic protein aggregates such as Ī²-amyloid and Ī±-synuclein trigger microglial NLRP3 activation, leading to caspase-1 activation and IL-1Ī² secretion. Both caspase-1 and IL-1Ī² contribute to disease progression in the mouse SOD1 model of amyotrophic lateral sclerosis (ALS), suggesting a role for microglial NLRP3. Prior studies, however, suggested SOD1 mice microglia do not express NLRP3, and SOD1 protein generated IL-1Ī² in microglia independent to NLRP3. Here, we demonstrate using Nlrp3-GFP gene knock-in mice that microglia express NLRP3 in SOD1 mice. We show that both aggregated and soluble SOD1 activates inflammasome in primary mouse microglia leading caspase-1 and IL-1Ī² cleavage, ASC speck formation, and the secretion of IL-1Ī² in a dose- and time-dependent manner. Importantly, SOD1 was unable to induce IL-1Ī² secretion from microglia deficient for Nlrp3, or pretreated with the specific NLRP3 inhibitor MCC950, confirming NLRP3 as the key inflammasome complex mediating SOD1-induced microglial IL-1Ī² secretion. Microglial NLRP3 upregulation was also observed in the TDP-43 ALS mouse model, and TDP-43 wild-type and mutant proteins could also activate microglial inflammasomes in a NLRP3-dependent manner. Mechanistically, we identified the generation of reactive oxygen species and ATP as key events required for SOD1 -mediated NLRP3 activation. Taken together, our data demonstrate that ALS microglia express NLRP3, and that pathological ALS proteins activate the microglial NLRP3 inflammasome. NLRP3 inhibition may therefore be a potential therapeutic approach to arrest microglial neuroinflammation and ALS disease progression

    In vitro screening of dry fruit extracts of Piper attenuatum for antioxidant and anticancer activity

    No full text
    Indian traditional medicinal plant Piper attenuatum (Buch-Ham) has been investigated for its antioxidant and anticancer activity. Three extracts were prepared using ethyl acetate, ethanol and methanol. In vitro antioxidant activity was performed by ABTS {2,2ā€²-azino-bis(3-ethylbenzothiazoline-6- sulphonic acid)} free radical scavenging method. All three extracts reduced the free radicals produced by ABTS in a concentration-dependent manner which could be compared to the standard (gallic acid). Invitro anticancer activity of all extracts was carried out by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide) assay method against MCF7 (Michigan Cancer Foundation-7) cell lines. None of the extract showed anticancer activity when compared with the standard (mitomycin C) indicating that P. attenuatum is deprived of antiproliferative or cytotoxic components
    corecore